Effectiveness of radioisotope therapy in bone metastases, based on personal experience
Authors:
- 1 January 2012
- journal article
- Published by Termedia Sp. z.o.o. in Contemporary Oncology
- Vol. 3, 201-205
Abstract
Aim of the study: Metastatic bone disease is a major clinical and therapeutic problem. It is particularly marked in patients with advanced breast and prostate cancer. Taking into account the diversity of the consequences of skeletal metastases, multidisciplinary patient care should be provided....Keywords
This publication has 22 references indexed in Scilit:
- Radioisotopes for metastatic bone pain2011
- A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastasesNuclear Medicine Communications, 2007
- 89Sr versus 153Sm-EDTMP: Comparison of treatment efficacy of painful bone metastases in prostate and breast carcinomaNuclear Medicine Communications, 2007
- Safety and efficacy of repeat administration of samarium Sm‐153 lexidronam to patients with metastatic bone painCancer, 2006
- Systemic radionuclide therapy in pain palliationAmerican Journal of Hospice and Palliative Medicine®, 2005
- The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone painJournal of Cancer Research and Clinical Oncology, 2004
- Metastatic bone disease: Clinical and therapeutic aspectsBone, 1992
- Strontium-89 chloride for pain palliation in prostatic skeletal malignancyBritish Journal of Radiology, 1991
- A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonateEuropean Journal of Cancer and Clinical Oncology, 1991
- Treatment of metastatic bone pain with strontium-89International Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, 1987